Literature DB >> 33284859

SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells.

Tapas Patra1, Keith Meyer1, Lizzie Geerling2, T Scott Isbell3, Daniel F Hoft1,2, James Brien2, Amelia K Pinto2, Ratna B Ray3, Ranjit Ray1,2.   

Abstract

Cytokine storm is suggested as one of the major pathological characteristics of SARS-CoV-2 infection, although the mechanism for initiation of a hyper-inflammatory response, and multi-organ damage from viral infection is poorly understood. In this virus-cell interaction study, we observed that SARS-CoV-2 infection or viral spike protein expression alone inhibited angiotensin converting enzyme-2 (ACE2) receptor protein expression. The spike protein promoted an angiotensin II type 1 receptor (AT1) mediated signaling cascade, induced the transcriptional regulatory molecules NF-κB and AP-1/c-Fos via MAPK activation, and increased IL-6 release. SARS-CoV-2 infected patient sera contained elevated levels of IL-6 and soluble IL-6R. Up-regulated AT1 receptor signaling also influenced the release of extracellular soluble IL-6R by the induction of the ADAM-17 protease. Use of the AT1 receptor antagonist, Candesartan cilexetil, resulted in down-regulation of IL-6/soluble IL-6R release in spike expressing cells. Phosphorylation of STAT3 at the Tyr705 residue plays an important role as a transcriptional inducer for SOCS3 and MCP-1 expression. Further study indicated that inhibition of STAT3 Tyr705 phosphorylation in SARS-CoV-2 infected and viral spike protein expressing epithelial cells did not induce SOCS3 and MCP-1 expression. Introduction of culture supernatant from SARS-CoV-2 spike expressing cells on a model human liver endothelial cell line (TMNK-1), where transmembrane IL-6R is poorly expressed, resulted in the induction of STAT3 Tyr705 phosphorylation as well as MCP-1 expression. In conclusion, our results indicated that the presence of SARS-CoV-2 spike protein in epithelial cells promotes IL-6 trans-signaling by activation of the AT1 axis to initiate coordination of a hyper-inflammatory response.

Entities:  

Year:  2020        PMID: 33284859     DOI: 10.1371/journal.ppat.1009128

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  53 in total

1.  Circulatory Exosomes from COVID-19 Patients Trigger NLRP3 Inflammasome in Endothelial Cells.

Authors:  Subhayan Sur; Robert Steele; T Scott Isbell; Ranjit Ray; Ratna B Ray
Journal:  mBio       Date:  2022-05-19       Impact factor: 7.786

2.  Lysozyme Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Inflammation in Human Corneal Epithelial Cells.

Authors:  Yinting Song; Haokun Zhang; Yanfang Zhu; Xiao Zhao; Yi Lei; Wei Zhou; Jinguo Yu; Xue Dong; Xiaohong Wang; Mei Du; Hua Yan
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

3.  SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production.

Authors:  Zhujun Ao; Maggie Jing Ouyang; Titus Abiola Olukitibi; Xiaojian Yao
Journal:  iScience       Date:  2022-07-14

4.  Role of Epithelial-Endothelial Cell Interaction in the Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

Authors:  Kenrie Pui-Yan Hui; Man-Chun Cheung; Ka-Ling Lai; Ka-Chun Ng; John Chi-Wang Ho; Malik Peiris; John Malcolm Nicholls; Michael Chi-Wai Chan
Journal:  Clin Infect Dis       Date:  2022-01-29       Impact factor: 9.079

5.  Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19.

Authors:  Maria A Pedrosa; Rita Valenzuela; Pablo Garrido-Gil; Carmen M Labandeira; Gemma Navarro; Rafael Franco; Jose L Labandeira-Garcia; Ana I Rodriguez-Perez
Journal:  Clin Sci (Lond)       Date:  2021-02-12       Impact factor: 6.124

6.  Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials.

Authors:  Rodolfo Pedro Rothlin; Mariano Duarte; Facundo Germán Pelorosso; Liliana Nicolosi; M Victoria Salgado; Héctor Miguel Vetulli; Eduardo Spitzer
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

7.  Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era.

Authors:  Ángel Serrano-Aroca; Kazuo Takayama; Alberto Tuñón-Molina; Murat Seyran; Sk Sarif Hassan; Pabitra Pal Choudhury; Vladimir N Uversky; Kenneth Lundstrom; Parise Adadi; Giorgio Palù; Alaa A A Aljabali; Gaurav Chauhan; Ramesh Kandimalla; Murtaza M Tambuwala; Amos Lal; Tarek Mohamed Abd El-Aziz; Samendra Sherchan; Debmalya Barh; Elrashdy M Redwan; Nicolas G Bazan; Yogendra Kumar Mishra; Bruce D Uhal; Adam Brufsky
Journal:  ACS Nano       Date:  2021-04-07       Impact factor: 15.881

Review 8.  The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime.

Authors:  Marco Chilosi; Venerino Poletti; Claudia Ravaglia; Giulio Rossi; Alessandra Dubini; Sara Piciucchi; Federica Pedica; Vincenzo Bronte; Giovanni Pizzolo; Guido Martignoni; Claudio Doglioni
Journal:  Mod Pathol       Date:  2021-04-21       Impact factor: 8.209

9.  Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.

Authors:  Matthew J McConnell; Nao Kawaguchi; Reiichiro Kondo; Aurelio Sonzogni; Lisa Licini; Clarissa Valle; Pietro A Bonaffini; Sandro Sironi; Maria Grazia Alessio; Giulia Previtali; Michela Seghezzi; Xuchen Zhang; Alfred I Lee; Alexander B Pine; Hyung J Chun; Xinbo Zhang; Carlos Fernandez-Hernando; Hua Qing; Andrew Wang; Christina Price; Zhaoli Sun; Teruo Utsumi; John Hwa; Mario Strazzabosco; Yasuko Iwakiri
Journal:  J Hepatol       Date:  2021-05-13       Impact factor: 25.083

10.  Exosomes from COVID-19 Patients Carry Tenascin-C and Fibrinogen-β in Triggering Inflammatory Signals in Cells of Distant Organ.

Authors:  Subhayan Sur; Mousumi Khatun; Robert Steele; T Scott Isbell; Ranjit Ray; Ratna B Ray
Journal:  Int J Mol Sci       Date:  2021-03-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.